Barinthus Bio Reports Second Quarter 2025 Financial Results and Updates on Corporate Developments

The final cohort of the single ascending dose (SAD) part of the Phase 1 A VALON trial initiated, with the SAD data readout expected early in the fourth quarter of 2025; The multiple ascending dose (MAD) part of the AVALON trial initiated; Available resources and cash runway guidance into 2027